Can neuroscience improve addiction treatment and policies?

Public Health Reviews

Volumn 35, Issue 2, 2014, Pages

  Nutt, David ^a   McLellan, A Thomas ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b TREATMENT RESEARCH INSTITUTE   (United States)

Author keywords

Addiction treatment; Alcohol; Drug policy; Neuroscience; Tobacco

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ACAMPROSATE; CANNABIS; DOPAMINE; DOPAMINE 2 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; NALMEFENE; NALTREXONE; OPIATE ANTAGONIST; PLACEBO; PSILOCYBINE; PSYCHEDELIC AGENT; RACLOPRIDE C 11; NEUROTRANSMITTER;

ADDICTION; ALCOHOLISM; BEHAVIOR CONTROL; DOPAMINE RELEASE; DRUG CONTROL; DRUG SELF ADMINISTRATION; EXECUTIVE FUNCTION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE EXPRESSION; HEROIN DEPENDENCE; HUMAN; IMPULSIVENESS; MOTIVATION; NEUROSCIENCE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PAIN; POSITRON EMISSION TOMOGRAPHY; POSTTRAUMATIC STRESS DISORDER; PUNISHMENT; REVIEW; REWARD; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; AMYGDALOID NUCLEUS; ARTICLE; BEHAVIOR; BRAIN FUNCTION; BRAIN MAPPING; DORSOLATERAL PREFRONTAL CORTEX; EATING; EXERCISE; GENETIC TRAIT; HEALTH CARE POLICY; HEREDITY; HIPPOCAMPUS; HORMONE METABOLISM; HORMONE RELEASE; MEDICAL RESEARCH; MEMORY; MOLECULAR DYNAMICS; NERVE CELL PLASTICITY; NEUROCHEMISTRY; NEUROIMAGING; NUCLEUS ACCUMBENS; ORBITAL CORTEX; PSYCHOLOGIC ASSESSMENT; SEX; SYSTEMATIC REVIEW; VENTRAL STRIATUM;

EID: 84899699493     PISSN: 03010422     EISSN: 21076952     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Volkow ND, Fowler JS, Wang GJ, Baler R, Telang F. Imaging dopamine's role in drug abuse and addiction. Neuropharmacology. 2009;56:3-8.
2. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A. 1988;85:5274-78.
3. Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci. 2005;8:1445-9. (Pubitemid 41573654)
4. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab. 2000;20:423-51. (Pubitemid 30164887)
5. Watson BJ, Taylor LG, Reid AG, Wilson SJ, Stokes PR, et al. Investigating expectation and reward in human opioid addiction with [11C]raclopride PET. Addict Biol. 5 July 2013; epub ahead of print.
6. Nutt DJ, Lingford-Hughes A. Addiction: the clinical interface. Br J Pharmacol. 2008;154:397-405. (Pubitemid 351670591)
7. Thanos PK, Volkow ND, Freimuth P, Umegaki H, Ikari H, Roth G, et al. Overexpression of dopamine D2 receptors reduces alcohol self-administration. J Neurochem. 2001;78:1094-103. doi:10.
8. Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F. Addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci U S A. 2011;108:15037-42.
9. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2009;35:217-38.
10. Dalley JW, Fryer TD, Brichard L, Robinson ES, Theobald DE, et al. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science. 2007;315:1267-70. (Pubitemid 46364262)
11. Volkow ND, Wang G-J, Fowler JS, Logan J, Gatley SJ, et al. Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am J Psychiatry. 1999;156:1440-43. (Pubitemid 29416545)
12. Martinez D, Saccone PA, Liu F, Slifstein M, Orlowska D, et al. Deficits in dopamine D(2) receptors and presynaptic dopamine in heroin dependence: commonalities and differences with other types of addiction. Biol Psychiatry. 2012;71:192-8.
13. Volkow ND, Wang GJ, Begleiter H, Porjesz B, Fowler JS, et al. High levels of dopamine D2 receptors in unaffected members of alcoholic families: possible protective factors. Arch Gen Psychiatry. 2006;63:999-1008. (Pubitemid 44330458)
14. Reid AG, Daglish MR, Kempton MJ, Williams TM, Watson B, et al. Reduced thalamic grey matter volume in opioid dependence is influenced by degree of alcohol use: a voxel-based morphometry study. J Psychopharmacol. 2008;22:7-10.
15. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature. 1997;386:830-3. (Pubitemid 27181256)
16. Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. Lancet. 2010;376:1558-65.
17. Weissenborn R, Nutt DJ. Popular intoxicants: what lessons can be learned from the last 40 years of alcohol and cannabis regulation? J Psychopharmacol. 2012;26:213-20.
18. Carter LP, Stitzer ML, Henningfield JE, O'Connor RJ, Cummings KM, Hatsukami DK. Abuse liability assessment of tobacco products including potential reduced exposure products. Cancer Epidemiol Biomarkers Prev. 2009;18:3241-62.
19. Krebs TS. Johansen PØ. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol. 2012;26:994-1002.
20. Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin. Psychiatry. 2006;67:1735-40. (Pubitemid 44955154)
21. Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol. 2010;25:439-52.
22. Nutt DJ, King LA, Nichols DE Effects of Schedule1 drug laws on neuroscience research and treatment innovation. Nature Rev Neurosci. 2013;14:577-85.
23. Carhart-Harris RL, Murphy K, Leech R, Erritzoe D, Wall MB, et al. The effects of acutely administered 3, 4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labelling and blood oxygen level-dependent resting-state functional connectivity. Biol Psychiatry. 2014; epub ahead of print.
24. Carhart-Harris RL, Leech R, Hellyer PJ, Shanahan M, Feilding A, et al. The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci. 2014;8:20.
25. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness. JAMA. 2000;284:1689-95.
26. McLellan AT, McKay JR, Forman R, Cacciola J, Kemp J. Reconsidering the evaluation of addiction treatment: from retrospective follow-up to concurrent recovery monitoring. Addiction. 2005;100:447-58. (Pubitemid 40529837)
27. McLellan AT, Skipper GS, Campbell M, DuPont RL. Five year outcomes in a cohort study of physicians treated for substance use disorders in the United States. BMJ. 2008;337:a2038.
28. Mann K, Bladström A, Torup L, Gual A, van den Brink W. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry. 2013;73:706-13.
29. Volkow ND, Wang GJ, Fowler JS, Tomasi, D. Addiction circuitry in the human brain. Annu Rev Pharmacol Toxicol. 2012;52:321-36.